Latest Us Market News

Cyclopharm’s Technegas has been recognised as the preferred ventilation agent in a pivotal draft US lung imaging guideline, signalling a major boost for its adoption in American clinical practice.

Pureprofile Limited has upgraded its FY26 revenue guidance after a record first half, driven by strong international growth and a booming platform business. The Rest of World segment now outpaces ANZ, signalling a major shift in the company’s geographic footprint.

Control Bionics has partnered with Tobii Dynavox to pilot its NeuroNode technology across five US states, aiming to enhance communication access for users of augmentative devices.

Botanix Pharmaceuticals reported a robust 28% increase in net revenue for Sofdra in Q2 FY26, driven by a 24% rise in prescriptions and a growing US sales team. The company maintains a strong cash position while navigating higher operating costs.

Echo IQ has completed clinical validation of its EchoSolv HF heart failure detection software with the Mayo Clinic Platform, achieving outstanding accuracy. The company has now formally submitted its FDA 510(k) clearance application, positioning itself for significant commercial expansion in the US healthcare market.

Life360 has reported its strongest quarter ever, with record user and subscriber growth in Q4 2025, surpassing full-year revenue and EBITDA guidance. The company forecasts continued momentum with 20% user growth expected in 2026.

Peak Processing has significantly expanded its manufacturing partnership with St. Peter’s Beverages, tripling its SKU production and boosting annual output by up to 700,000 units. This move strengthens its foothold in North America’s cannabis beverage market using proprietary technology.

American Tungsten & Antimony Ltd is progressing its Nasdaq listing plans with a confidential SEC filing expected in March 2026 and has appointed Deutsche Bank as ADR depositary alongside a new CFO to support growth.

Connexion Mobility reported a slight revenue decline in Q2 FY26 but boosted net profit before tax by 18%, supported by expense cuts and steady subscription growth. The company’s strategic focus on expanding OEM and dealership relationships continues amid near-term sales team reductions.

LTR Pharma has initiated dosing in its Phase II clinical trial for SPONTAN, a rapid-acting intranasal spray targeting erectile dysfunction, marking a key step toward FDA approval and commercial expansion.

Adveritas Limited has reported a record $14.25 million annualised recurring revenue for the December 2025 quarter, driven by strong US market growth and AI-enhanced product development. The company’s strategic focus on media agency partnerships and new product lines signals robust momentum ahead.

QuickFee Limited reports flat Q2 FY26 revenue with a 4% rise in H1, completes a significant capital return, and sets a positive outlook with new US reseller partnerships.